Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07234526

Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients

Pre-Antibiotic Glucose Fluctuations and Glycemic Shock Index as a Predictor of Sepsis Severity and Clinical Outcomes in ICU Patient

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
105 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine whether glucose fluctuations prior to antibiotic administration are associated with sepsis severity and poor clinical outcomes. * To assess if the time to Glycemic Normalization after Antibiotic Initiation can be used as an Early Prognostic Indicator in Sepsis. * To evaluate the Glycemic Shock Index (GSI) as a Combined Marker of Hemodynamic and Metabolic Stress in ICU Sepsis Patients.

Detailed description

Sepsis is a life-threatening condition caused by the body's overwhelming response to infection. It is a major cause of death in intensive care units (ICUs) despite advances in treatment. One of the body's common responses to sepsis is a disturbance in blood sugar levels, even in patients without diabetes. These changes, known as glycemic variability, include both high and low glucose levels and rapid swings between them. Recent studies suggest that glycemic variability the early hours of sepsis may be linked to worse outcomes, including organ failure and death .Unlike average glucose levels, these fluctuations can reflect how stressed the body is. A newer marker called the Glycemic Shock Index (GSI) - calculated by dividing blood glucose by mean arterial pressure (MAP)- may help capture both metabolic and circulatory stress. Another factor of interest is the time it takes for blood sugar to return to normal after starting antibiotics. Early normalization may signal a better response to treatment, while persistent abnormal levels could predict complications. Understanding how early glucose changes relate to sepsis severity may help us identify high-risk patients sooner. This study focuses on glucose fluctuations before antibiotics, time to glucose normalization, and GSI, and how they relate to outcomes like mortality, organ failure like AKI and ICU stay.

Conditions

Timeline

Start date
2026-12-01
Primary completion
2028-12-01
Completion
2029-06-01
First posted
2025-11-18
Last updated
2025-11-19

Source: ClinicalTrials.gov record NCT07234526. Inclusion in this directory is not an endorsement.